Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 4:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 114 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immunocompromised Clear all
Recruiting Phase 1 Interventional

T Cell Therapy Opposing Novel COVID-19 Infection in Immunocompromised Patients

NCT05141058
View directory record Official record
Conditions
SARS-CoV-2 Infection
Interventions
Coronavirus-specific T cell (CST)
Biological
Lead sponsor
Children's National Research Institute
Other
Eligibility
2 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 26, 2026, 4:24 PM EDT
Completed Phase 3 Interventional Results available

A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.

NCT00545532
View directory record Official record
Conditions
Influenza, Human
Interventions
oseltamivir, placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
1 Year and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
60
States / cities
Birmingham, Alabama • Beverly Hills, California • Burbank, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Oct 26, 2026, 4:24 PM EDT
Completed Phase 1 Interventional

A Pharmacokinetic/Pharmacodynamic Study of Oseltamivir in Immunocompromised Children With Confirmed Influenza Infection

NCT01715909
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Up to 12 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
7
States / cities
Palo Alto, California • Aurora, Colorado • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 26, 2026, 4:24 PM EDT
Completed Phase 2 Interventional

An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection

NCT01924793
View directory record Official record
Conditions
Parainfluenza
Interventions
DAS181-F02 Dry Powder in Bulk, DAS181-F02 Nebulized Formulation Inhaled Dose
Drug
Lead sponsor
Ansun Biopharma, Inc.
Industry
Eligibility
12 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
23
States / cities
Duarte, California • Orange, California • Palo Alto, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 26, 2026, 4:24 PM EDT
Recruiting Not applicable Interventional

Microbial Cell-free Metagenomic Sequencing for Suspected Infections in Adult Immunocompromised Outpatients

NCT07110636
View directory record Official record
Conditions
Infection, Infections, Bacterial, Infections, Fungal, Infection Viral, Parasitic Disease
Interventions
Metagenomic plasma-based test for agnostic pathogen detection
Diagnostic Test
Lead sponsor
Karius, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
San Francisco, California • New Orleans, Louisiana • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 26, 2026, 4:24 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Natural History, Epidemiology and Pathogenesis of Severe HPV-Related Diseases (Neptune)

NCT05026138
View directory record Official record
Conditions
Human Papillomavirus
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 100 Years
Enrollment
850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2047
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 26, 2026, 4:24 PM EDT
Terminated Phase 2 Interventional Results available

Booster Dose Trial

NCT05016622
View directory record Official record
Conditions
Cancer
Interventions
BNT162b2 vaccine
Biological
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 26, 2026, 4:24 PM EDT
Terminated Phase 1 Interventional

Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T Cells

NCT03798301
View directory record Official record
Conditions
CMV Infection, Cytomegalovirus Infections, CMV Viremia, Opportunistic Infections
Interventions
CMV-specific T-cells
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
1 Month and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 26, 2026, 4:24 PM EDT
Recruiting Not applicable Interventional

Remote Temperature Monitoring of Patients At Risk for Developing Fever

NCT06752512
View directory record Official record
Conditions
Fever, Cancer, Remote Patient Monitoring
Interventions
Remote Patient Monitoring
Device
Lead sponsor
AION Biosystems
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Schenectady, New York
Source: ClinicalTrials.gov public record
Updated Dec 30, 2024 · Synced Oct 26, 2026, 4:24 PM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

NCT07013474
View directory record Official record
Conditions
COVID-19 Infection
Interventions
ibuzatrelvir, remdesivir, placebo for ibuzatrelvir, placebo for remdesivir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
70
States / cities
Canoga Park, California • Granada Hills, California • La Jolla, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 26, 2026, 4:24 PM EDT
Completed No phase listed Observational Results available

COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States

NCT05020145
View directory record Official record
Conditions
Immunocompromised, Immunosuppressed, Covid-19, SARS-COV-2, SARS-COV-2 Infection, Breakthrough Infection
Interventions
BNT162b2 (Tozinameran)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
1,277,747 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Oct 26, 2026, 4:24 PM EDT
Completed Not applicable Interventional

Evaluation of Amphotericin B in the Treatment of Biopsy Proven Candida Esophagitis in Immunocompromised Patients

NCT00002041
View directory record Official record
Conditions
Candidiasis, Esophageal, HIV Infections
Interventions
Amphotericin B
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 2, 2007 · Synced Oct 26, 2026, 4:24 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Influenza Vaccine in Lung Transplant Patients - Persistence of Antibodies Beyond the Season

NCT04530786
View directory record Official record
Conditions
Influenza
Interventions
Influenza vaccine
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 23, 2020 · Synced Oct 26, 2026, 4:24 PM EDT
Recruiting Phase 2 Interventional

Third Party Viral Specific T-cells (VSTs)

NCT02532452
View directory record Official record
Conditions
Viral Infection, Viral Reactivation, Infection in an Immunocompromised Host
Interventions
Viral Specific VST Infusion
Biological
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
2 Days and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
4
States / cities
Akron, Ohio • Cincinnati, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 26, 2026, 4:24 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults

NCT05074433
View directory record Official record
Conditions
Immunocompromised
Interventions
casirivimab+imdevimab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
66
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Long Beach, California + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 26, 2026, 4:24 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons

NCT07050732
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
Arexvy (2 doses total), Arexvy (3 doses total), Arexvy (1 dose total), Placebo
Biological · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 26, 2026, 4:24 PM EDT
Terminated Phase 1 Interventional

Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients

NCT05101213
View directory record Official record
Conditions
Adenovirus Infection, BK Virus Infection, Cytomegaloviral Infection, Hematopoietic and Lymphoid Cell Neoplasm, JC Virus Infection, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Virus-specific Cytotoxic T-lymphocytes
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 26, 2026, 4:24 PM EDT
Completed Not applicable Interventional

A Study of Stavudine in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drugs

NCT00002308
View directory record Official record
Conditions
HIV Infections
Interventions
Stavudine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1991
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 5, 2011 · Synced Oct 26, 2026, 4:24 PM EDT
Completed Phase 3 Interventional

Caspofungin to Prevent Candidiasis in Adults in Hospital Intensive Care Units

NCT00099775
View directory record Official record
Conditions
Candidiasis
Interventions
Caspofungin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 26, 2026, 4:24 PM EDT
Terminated Phase 2 Interventional Results available

Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma

NCT01964755
View directory record Official record
Conditions
Epstein Barr Virus Associated Non Hodgkin's Lymphoma, Epstein Barr Virus Associated Hodgkin's Lymphoma, Post-Transplant Lymphoproliferative Disease
Interventions
Doxorubicin, Methotrexate, Leucovorin, Hydroxyurea, Zidovudine, Rituximab
Drug · Biological
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
2
States / cities
Miami, Florida • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Oct 26, 2026, 4:24 PM EDT
Completed Phase 2 Interventional Results available

A Safety and Tolerability Study of Sotrovimab (VIR-7831) Prophylaxis Against COVID-19 in Immunocompromised Individuals

NCT05210101
View directory record Official record
Conditions
SARS CoV 2 Infection
Interventions
Sotrovimab
Drug
Lead sponsor
Sophia Koo, M.D.
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Oct 26, 2026, 4:24 PM EDT
Completed No phase listed Observational

Pneumonia in the ImmunoCompromised - Use of the Karius Test for the Detection of Undiagnosed Pathogens

NCT04047719
View directory record Official record
Conditions
Pneumonia, Bacterial, Pneumonia, Viral, Pneumonia Fungal, Pneumonia Cavitary, Immunocompromised Host
Interventions
Karius Test
Diagnostic Test
Lead sponsor
Karius, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
10
States / cities
Duarte, California • San Francisco, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 26, 2026, 4:24 PM EDT
Completed Phase 1 Interventional Results available

Safety Study to Evaluate FluMist in Immunocompromised Children

NCT00112112
View directory record Official record
Conditions
Cancer
Interventions
FluMist, Placebo
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
5 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
5
States / cities
Rochester, New York • Stony Brook, New York • Memphis, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Oct 26, 2026, 4:24 PM EDT
Completed Phase 1 Interventional

The Pilot Study of Foscarnet Cream in the Treatment of Mucocutaneous Herpes Simplex Virus Infections in Immunocompromised Patients Unresponsive to Acyclovir Treatment

NCT00002144
View directory record Official record
Conditions
Herpes Simplex, HIV Infections
Interventions
Foscarnet sodium
Drug
Lead sponsor
Astra USA
Industry
Eligibility
13 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 26, 2026, 4:24 PM EDT